New FDA Approval for CML Patients

Asciminib (Scemblix) was recently approved for the following indications:

For patients with Philadelphia chromosome– positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with two or more tyrosine kinase inhibitors.

For patients with Ph+ CML in chronic phase with a T315I mutation

Here at Belong, we will continue to update you with new medical and research developments. If you are interested in clinical trial-related info or in participating in such a trial, you are invited to respond here or contact us in the “Find Clinical Trials” group.

Best of health,
The Clinical Trial Team

For more info:

This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment

7 Ways to Stay Organized With Your Cancer Care

Staying organized during cancer treatment can help reduce stress and make daily life a little…

How Does MS Affect The Bladder?

More than 50% of patients with MS will experience urinary issues during their illness. Overactive…

Anti-Nausea Drugs and Their Side Effects

Cancer treatments can often cause nausea and vomiting, and to help manage this, doctors prescribe…

When your Body Moves or Shakes Uncontrollably

Do you sometimes feel like your whole body or even just a part of it moves…

Understanding TIL Therapy

TIL therapy, short for Tumor-Infiltrating Lymphocyte therapy, is an advanced immunotherapy type that uses your…

How to Talk About Your Cancer Diagnosis?

Telling people you have cancer can feel overwhelming. You might not feel ready to talk,…